Cellectis S.A. (CMVLF)
| Previous close | 7.04 |
| Open | 7.04 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.03 - 7.04 |
| 52-week range | 7.03 - 33.48 |
| Volume | |
| Avg. volume | 329 |
| Market cap | 326.634M |
| Beta (5Y monthly) | 2.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.92 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights12/31/202145,484,81051,085,782 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunoth
- Zacks
Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA
The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.
- GlobeNewswire
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
• Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene’s Manufacturing Process • Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 2022 Pending FDA Discussion NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapie
